Vor Biopharma (VOR) Liabilities and Shareholders Equity (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $506.7 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 363.58% year-over-year to $506.7 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 165.31% increase from a year earlier, with the FY2025 full-year figure at $464.1 million, up 224.81% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $506.7 million, up from $464.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for VOR reached as high as $506.7 million in Q1 2026 and fell as low as $109.3 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $232.0 million across 5 years, with a median of $206.4 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity plunged 47.99% in 2024 and jumped 363.58% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $299.4 million in 2022, then tumbled by 33.82% to $198.1 million in 2023, then slipped by 27.88% to $142.9 million in 2024, then soared by 224.81% to $464.1 million in 2025, then rose by 9.18% to $506.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $506.7 million in Q1 2026, $464.1 million in Q4 2025, and $176.2 million in Q3 2025.